STERIS (NYSE:STE) Releases FY 2027 Earnings Guidance

STERIS (NYSE:STE) updated its FY 2027 earnings guidance on Monday. The company provided earnings per share guidance of 11.100-11.300 for the period, compared to the consensus earnings per share estimate of 11.070. The company issued revenue guidance of $6.4 billion-$6.4 billion, compared to the consensus revenue estimate of $6.3 billion.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the stock. Weiss Ratings lowered shares of STERIS from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Thursday, April 16th. Wall Street Zen lowered shares of STERIS from a “strong-buy” rating to a “buy” rating in a research report on Sunday, April 26th. Five equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, STERIS presently has a consensus rating of “Moderate Buy” and an average price target of $275.20.

STERIS Stock Performance

NYSE STE opened at $210.90 on Wednesday. STERIS has a 52-week low of $195.14 and a 52-week high of $269.44. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.75 and a current ratio of 2.48. The company has a market capitalization of $20.68 billion, a P/E ratio of 26.60 and a beta of 0.95. The company has a fifty day moving average of $221.54 and a 200-day moving average of $243.52.

STERIS (NYSE:STE) last posted its quarterly earnings data on Monday, May 11th. The medical equipment provider reported $2.83 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.86 by ($0.03). STERIS had a return on equity of 14.23% and a net margin of 13.18%.The company had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $1.59 billion. During the same period in the prior year, the firm posted $2.74 earnings per share. The business’s revenue was up 6.7% on a year-over-year basis. STERIS has set its FY 2027 guidance at 11.100-11.300 EPS. As a group, equities research analysts predict that STERIS will post 11.04 EPS for the current fiscal year.

STERIS Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 26th. Shareholders of record on Monday, June 8th will be paid a $0.63 dividend. The ex-dividend date of this dividend is Monday, June 8th. This represents a $2.52 annualized dividend and a yield of 1.2%. STERIS’s payout ratio is currently 31.78%.

Insiders Place Their Bets

In other STERIS news, Director Cynthia L. Feldmann sold 3,098 shares of the business’s stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $237.21, for a total value of $734,876.58. Following the completion of the sale, the director directly owned 705 shares of the company’s stock, valued at $167,233.05. The trade was a 81.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 1.07% of the stock is owned by corporate insiders.

Key STERIS News

Here are the key news stories impacting STERIS this week:

• Positive Sentiment: STERIS gave FY2027 EPS guidance of $11.10 to $11.30, which came in above the consensus estimate, signaling management expects continued earnings growth. Reuters article
• Positive Sentiment: The board authorized a new $1 billion share repurchase program, which can support the stock by reducing share count over time and signaling confidence in the business. Quiver Quantitative article
• Positive Sentiment: Full-year fiscal 2026 revenue from continuing operations rose 9%, showing the business continues to grow despite the earnings miss. GlobeNewswire article
• Neutral Sentiment: Fourth-quarter revenue growth was healthy, but the top line still slightly missed expectations, so investors may view the quarter as good but not enough to justify a major rerating. Zacks article
• Negative Sentiment: Q4 EPS missed estimates, which is the main reason some traders are selling on the results despite the upbeat outlook. Zacks article

Institutional Trading of STERIS

Several hedge funds have recently added to or reduced their stakes in the business. T. Rowe Price Investment Management Inc. lifted its stake in STERIS by 40.6% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 12,484 shares of the medical equipment provider’s stock worth $3,165,000 after purchasing an additional 3,607 shares during the last quarter. Compound Planning Inc. bought a new stake in STERIS in the fourth quarter worth $220,000. Invesco Ltd. increased its position in shares of STERIS by 10.2% in the fourth quarter. Invesco Ltd. now owns 1,410,612 shares of the medical equipment provider’s stock valued at $357,618,000 after acquiring an additional 130,470 shares during the period. Mercer Global Advisors Inc. ADV raised its stake in shares of STERIS by 39.1% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 20,066 shares of the medical equipment provider’s stock valued at $5,087,000 after acquiring an additional 5,644 shares during the last quarter. Finally, EP Wealth Advisors LLC purchased a new stake in shares of STERIS during the fourth quarter worth about $720,000. 94.69% of the stock is owned by institutional investors.

About STERIS

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.